Type 2 Diabetes news from FierceBiotech
News
Sanofi: Acomplia demonstrates better glucose control
Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more Read more...
Syndexa gets $15M for metabolic disease work
With help from technology entrepreneur Dr. Yalcin Ayasli, Cambridge, MA-based Syndexa Pharmaceuticals has garnered $15 million in a second round of financing. The company previously raised about $4 Read more...
ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
> Jim Reddoch, a biotech analyst with Friedman, Billings & Ramsey, is raising some interesting questions about Genentech's second-generation Read more...
Transition inks $137M diabetes collaboration with Lilly
Eli Lilly has signed on to collaborate with Transition Therapeutics on the development of Transition's diabetes therapies. Transition will pocket a $7 million upfront fee and stands to gain up to Read more...
SPOTLIGHT: Takeda NDA triggers milestone
The FDA has accepted Takeda Pharmaceutical's NDA for alogliptin, a DPP-4 inhibitor for type 2 diabetes. The FDA's acceptance of the NDA filing triggers a $15 million milestone payment to PPD. Read more...
Phenomix outlines its shot at an IPO
Phenomix says now is the time to go public. The San Diego-based drug developer has filed papers with the SEC that outline an initial public offering designed to raise $86 million. Phenomix has Read more...
Lilly submits prasugrel NDA
Eli Lilly and Daiichi Sankyo have submitted the much-watched drug prasugrel to the FDA. The drug--an oral antiplatelet agent--is poised to take on the blockbuster Plavix. Read more...
ALSO NOTED: Anemia drugs back in the spotlight; Biodel completes VIAject enrollment; and much more...
> The FDA has revealed two new studies that show cancer patients may be more likely to die while using Amgen's blockbuster drugs Aranesp and Epogen (also sold under the brand name Procrit by Read more...
Novo: no pancreatitis risk linked to Liraglutide
Hoping to calm worries spark by a recent announcement by the FDA that the diabetes drug Byetta is linked to a higher risk of acute pancreatitis, Novo Nordisk said that there is nothing in its data Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends